scholarly article | Q13442814 |
P50 | author | Bruce M. Psaty | Q30429993 |
Jcm Meijers | Q68093274 | ||
Susan R Heckbert | Q88077554 | ||
Thomas Lumley | Q102228619 | ||
P2093 | author name string | Rosendaal FR | |
Reiner AP | |||
Smith NL | |||
Doggen CJ | |||
Lemaitre RN | |||
P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
Pharmacokinetic and pharmacologic variation between different estrogen products | Q28271356 | ||
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study | Q28368332 | ||
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial | Q29615226 | ||
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
The pharmacokinetics and efficacy of different estrogens are not equivalent | Q32067302 | ||
Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 | ||
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis | Q34356168 | ||
Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism | Q34451410 | ||
Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women | Q38504402 | ||
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors | Q42646583 | ||
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial | Q43795711 | ||
Replacing short-acting nifedipine with alternative medications at a large health maintenance organization | Q43882432 | ||
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women | Q44242587 | ||
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women | Q44429143 | ||
Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study | Q44472887 | ||
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial | Q44517324 | ||
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study | Q44666769 | ||
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate | Q45154446 | ||
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies | Q45197770 | ||
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide | Q46470688 | ||
Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women | Q46594043 | ||
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women | Q47741055 | ||
Determinants of the APTT- and ETP-based APC sensitivity tests. | Q53853713 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | activated protein C resistance | Q296104 |
drotrecogin alfa | Q412888 | ||
P304 | page(s) | 1701-1706 | |
P577 | publication date | 2006-08-01 | |
P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
P1476 | title | The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women | |
P478 | volume | 4 |
Q55982498 | Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women |
Q37727617 | Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers |
Q28607716 | Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens |
Q37238147 | Venous thromboembolism in women |
Search more.